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Summary We have examined the role of the aromatase inhibitor 4-hydroxyandrostenedione (4-OHA) in the
prevention of mammary tumourigenesis in experiments involving 170 rats. We first demonstrated a prophyl-
actic effect of 4-OHA (50 mg/week) in reducing tumour incidence over a 30 week period compared to controls
(P = 0.04). We repeated the experiment to determine optimum dose and duration of therapy. Although
4-OHA again prevented tumour development (P<0.0005), there was no difference between the standard
(50 mg/week) dose and the higher dose (100 mg/week). Rats were randomised at 30 weeks to either stop or to
continue prophylactic therapy; marginal benefit in tumour free survival in continuing therapy was observed
(P = 0.03). We conclude that 4-OHA is an effective agent in preventing carcinogen-induced mammary
tumours in rats and further studies of the role of oestrogen synthesis inhibitors in the prevention of human
mammary tumours may be indicated.
There is now substantial evidence that oestrogens have a
major role in the etiology of breast cancer and that anti-
endocrine agents used prophylactically may diminish the inci-
dence of the disease (Jordan et al., 1980).
In premenopausal women, ovariectomy reduces breast
cancer incidence (Trichopoulos et al., 1972), whilst in post-
menopausal women an analogous reduction of serum oest-
radiol is best achieved by aromatase inhibition (Coombes et
al., 1984). An alternative strategy would be to use an anti-
oestrogen but the anti-oestrogens in current use notably
tamoxifen, are all weak agonists as well as being potent
antagonists. Despite these disadvantages, tamoxifen has
become the most widely used agent in postmenopausal
patients as a means of preventing distant recurrence after
primary tumour excision (Early Breast Cancer Trialists' Col-
laborative Group, 1989) and has been suggested as a candi-
date for preventing mammary tumourigenesis (Gazet, 1986).
It has already been shown that tamoxifen and 4-hydroxy-
androstenedione (4-OHA) cause significant tumour regression
of nitrosomethylurea (NMU) induced rat mammary tumours
(Wilkinson et al., 1986). NMU-induced tumours are bio-
logically similar to hormone responsive human breast car-
cinomas in that they contain significant amounts of oestrogen
receptor (ER), (Williams et al., 1981). It is likely that most
early human breast carcinomas are ER positive, but as they
become more undifferentiated they lose their ability to syn-
thesise ER and growth becomes independent of oestrogen
stimulation (Taylor et al., 1982). As such the prophylaxis of
human breast tumourigenesis by early endocrine intervention
is receiving increased attention (Gazet, 1986; Fentiman, 1989;
Powles et al., 1989).
Our paper reports on the effects of 4-OHA on the develop-
ment of NMU-induced rat mammary carcinomas, and ex-
amines the effect of drug dosage and duration of preventive
therapy.
Methods
Carcinogen exposure
Three batches, 40 animals in the first two batches and 90 in
the third, of female Ludwig/Wistar/Olac rats (OLAC 1976
Ltd, Oxon, England), were kept at 19°C in isolators with a
regimen of 12 h light/day. They were fed C.R.M. diet (Lab-
sure, Croydon, England) and received water ad libitum.
Nitrosomethylurea (NMU) was dissolved in distilled water at
12.5 mg ml-' and adjsuted to pH 5.4 with acetic acid. At
45-50 days of age, the rats received 0.5 ml NMU/rat
(5 mg 100 g-' body weight) subcutaneously in both flanks on
days 0, 14 and 28. When transferred to the institute, the
animals were kept at 22-23°C with 12 h light/12 h dark
(7 am-7 pm-light cycle) and fed a diet rich in polyun-
saturated fats (14% fat diet obtained from Labsure,
Croydon, England).
Anti-endocrine injection schedule
Study I (batch I and batch 2) Batch 1 started the study 3
months before batch 2. Within 1 week after the final car-
cinogen injection, all animals were divided randomly into two
groups. The control group received intramuscularly, 0.2 ml,
0.9% NaCl solution per rat per week. The treatment group
received 50 mg 4-hydroxyandrostenedione (4-OHA) (Ciba-
Geigy, Basel, Switzerland) subcutaneously per rat per week.
This was supplied as a sterile microcrystalline powder
suspended in physiological saline immediately before
administration. All animals were injected once a week for 30
weeks.
Study 2, batch 3 In batch 3, each animal was randomised to
receive either 0.2 ml, 0.9% NaCI solution, 4-OHA 50 mg 5-6
weekly or 100 mg week for 30 weeks. Each group therefore
contained 30 animals. At 30 weeks, those rats remaining in
the trial were randomised a second time (within their respec-
tive treatment group) either to continue treatment until 60
weeks or to stop therapy.
At the start of the anti-endocrine injection schedule all rats
were approximately the same age and weight and free of
tumours.
Assessment ofmammary tumour incidence
Animals were examined weekly for palpable tumours, with
date of tumour appearance and a map of tumour location
recorded for each rat. Tumour size was measured weekly
using Vernier calipers. If a tumour attained a size of 15 mm
in diameter, the rat was sacrificed by cardiac puncture and
tumours excised. Rats which did not develop a tumour by
the end of the study period (study 1 = 30 weeks, study 2
= 60
weeks) were sacrificed by cardiac puncture. The incidence of
tumours in the control group is similar to our previous
studies (Wilkinson et al., 1986).
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Statistical methods
Standard survival analysis methods, namely Kaplan-Meier
survival curves and the Logrank test, were used to compare
tumour occurrence and survival between groups. Since small
tumours often regress spontaneously, only those tumours
10 mm in diameter or greater were considered in the analysis
of tumour incidence. Sacrifice of an animal due to the occur-
rence of a 15 mm tumour was considered as a death.
The relative risk of tumour occurrence and death in
treated rats compared with controls and the possibility of a
treatment interaction, were estimated using Cox regression
(Cox & Oakes, 1984).
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Figure 1 Study 1: Tumour free survival control;
4-OHA treated.
Results
Study I
Table I shows the status of rats at 14 and 30 weeks. It is
clear from the table that the risk of tumour development and
particularly the number of fatalities is different between the
two batches. For this reason all analyses have been stratified
by batch. In all cases death was due to progressive mammary
tumour growth, as detailed above.
Figure 1 shows the tumour free survival for batches 1 and
2 combined. Comparison between controls and 4-OHA treated
rats, suggests longer tumour free survival for the 4-OHA
treated rats than for the control group (Logrank test
= 4.34 d.f. = 1 P = 0.04). There is no evidence of any
difference in the magnitude of the risk reduction with 4 OHA
between the two batches (test for interaction, P = 0.60).
Figure 2 shows the corresponding overall survival. We
observe some evidence of a better survival in 4-OHA treated
rats than controls (Logrank test = 5.81 d.f. = 1 P = 0.02).
Again there is no evidence of an interaction with batch
(P = 0.19).
Study 2
Table II and Figures 3 and 4 show the results of the second
study which examined the dose response relationship of
4-OHA.
There is a highly significant difference between control rats
and those treated with 4-OHA, both in terms of tumour free
survival (Logrank test for trend = 29.49 d.f. = 1 P <0.0005,)
and overall survival (Logrank test for trend = 23.22 d.f.
= IP <0.0005), confirming the results of the first study.
There is, however, no evidence of any difference in tumour
free survival or overall survival between the 50 mg and
100 mg groups (Logrank test = 0.16 d.f. = 1 P = 0.7 and
Logrank test = 0.09 d.f. = 1 P = 0.8 respectively.
At 30 weeks 57% (95% CI 39%, 73%) of the controls
were alive compared with 100% for both 50 mg and 100 mg
treated groups. At 60 weeks, only 13% of animals in the
control group were surviving (95% CI 49, 28%) compared
with 53% (95% CI 36%, 70%) and 57% (95% CI 39%,
73%) in the 50mg and 100mg respectively.
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Figure 3 Study 2: Tumour free survival control;
4-OHA 50mg treated; ---------- 4-OHA 100 mg treated.
Table II Study 2: Status of animals during the study period
Group
50 mg 100mg
Controls 4-OHA 4-OHA
Time No. (%) No. (%) No. (%)
(a) 15 weeks
Aliveand tumour-free 26(87) 30(100) 30(100)
Dead 2(7) 0(0) 0(0)
(b) 30weeks
Aliveand tumour-free 14(47) 30(100) 30(100)*
Dead 13 (43) 0(0) 0(0)*
(c) 60weeks
(continually treated group)
Aliveand tumour-free 3 (10) 11 (37)** 9(30)
Dead 26(87) 4(13) 6(20)
(d) 60weeks
(treatment stopped at 30 weeks)
Aliveand tumour-free 3 (10) 4(13) 8 (27)
Dead 26(87) 10(37) 7(23)
*P = <0.0005 when compared to controls. **P = 0.03 when
compared to those that stopped treatment.
Table I Study 1; Status of animals during study period
Batch I Batch 2
Alive and Tumour Alive and Tumour
disease free > 10 mm Dead disease free >10 mm Dead
14 weeks
Controls 12 (60%) 1 (5%) 7 (35%) 17 (85%) 1 (5%) 2 (10%)
4-OHA 19 (95%) 1 (5%) 0 (0%) 19 (95%) 0 (0%) 1 (5%)
30 weeks
Controls 6 (30%) 1 (5%) 13 (65%) 11 (55%) 4 (20%) 5 (25%)
4-OHA 15 (75%) 0 (0%) 5 (25%) 14 (70%)* 2 (10%) 4 (20%)
*P = <0.04.
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Treatment after 30 weeks
All treated rats survived to 30 weeks and were therefore
randomised a second time to determine whether or not treat-
ment should be continued. Overall there is evidence of lower
tumour incidence (Figure 5) in the group continuing treat-
ment (Logrank test (stratified for dose) = 4.68 d.f. = 1P
= 0.030) and somewhat weaker evidence of improved sur-
vival (Figure 6) (Logrank test (stratified for dose) = 3.44 d.f.
=1P = 0.064).
There is also some suggestion that benefit of continuing
therapy is largely confined to the 50 mg group; we observe a
significant benefit in terms of tumour free survival of con-
tinuing treatment for the 50 mg group (Logrank test
= 7.16 d.f. 1 P = 0.007), but not for the 100 mg group (Log-
rank test = 0.33 d.f. = 1 P = 0.54). We observe, however, no
evidence of an interaction between duration of treatment and
dose of 4-OHA given (test for interaction P = 0.16).
Similar results are obtained when considering overall sur-
vival (Logrank test = 5.11 d.f. = 1 P = 0.Q24 and Logrank
test =0.38d.f.= 1P =0.54 for the 50mg and 100mg
groups respectively). Again no evidence of an interaction
with dose of 4-OHA (test for interactiQn P = 0.25) is
observed.
Survival estimates at 60 weeks in each of these groups are
shown in Table III.
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Figure 3 Study 2: Tumour free survival control;
4-OHA 50mg treated; ---------- 4-OHA 100mg treated.
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Figure 4 Study 2: Survival control; ---- 4-OHA
50mg treated; 4-OHA 100mg treated.
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Figure 5 Study 2: Tumour free survival after 30 weeks
50mg 4-OHA stopped at 30 weeks; -- 50mg 4-
OHA continued after 30 weeks; 100mg 4-OHA stop-
ped at 30 weeks; ---- 100 mg 4-OHA continued after 3 weeks.
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Figure 6 Study 2: Survival after 30 weeks 50 mg
4-OHA stopped at 30 weeks; -- 50 mg 4-OHA continued after
30 weeks; 100 mg 4-OHA stopped at 30 weeks;
100mg 4-OHA continued after 3 weeks.
Combining data from both studies, the estimated relative
risk of death during the first 30 weeks in the control group
compared with the 4-OHA treated groups is 5.8 (95% CI 2.7,
12.3). The corresponding relative risk for tumour incidence is
4.5 (95% CI, 2.4, 8.1).
Discussion
Our results show that 4-OHA can prevent mammary tumour
development and improve survival in rats bearing mammary
tumours. During the first 30 weeks 4-OHA prevented
development of an estimated 78% of tumours and 83% of
deaths.
4-OHA is an important new agent in the treatment of
human breast cancer (Coombes et al., 1984; Goss et al.,
1986), and is effective in lowering serum oestradiol in post-
menopausal women. There are no other endocrine effects
known except that, at high oral dosing, its low androgenicity
(1%) is seen, reflected by a reduction in sex hormone binding
globulin. 4-OHA is not effective in premenopausal women
when administered as a single agent. We do however, see a
further reduction in serum oestradiol when 4-OHA is given
in conjunction with an LHRH analogue (Stein et al., 1989).
Table III Survival estimates at 1 year
4-OHATreatmentGroup 60week survival (95% Confidence Interval)
50 mg -stopped treatment at 33% (14%, 59%)
30weeks
50 mg -continued treatment 73% (49%, 91%)
after 30weeks
100 mg -stopped treatment 53% (29%, 77%)
at 30weeks
100 mg -continued treatment 60% (35%, 82%)
after 30weeks
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Our results suggest that low dose, longer duration therapy
may be the more effective treatment. The reason for this is
not clear. It is possible that at higher doses the androgenic
effect of 4-OHA impedes its activity. Alternatively, a hitherto
unknown metabolite may have oestrogenic activity at higher
dose. In any event, our results suggest that high dose
aromatase inhibition is not needed to prevent mammary
carcinogenesis.
Several further questions remain before this therapy can be
advocated for women at high risk of developing breast
cancer. Firstly, there may be more powerful aromatase
inhibitors in development. We have already shown that
CGS16949A, an imidazole derivative, is effective in patients
with breast cancer (Stein et al., in press) and this is also
effective in rats bearing mammary tumours (Schieweck et al.,
1988). Secondly, longer term toxicity testing is needed in both
animals and humans, and thirdly it is important to determine
that 4-OHA is as effective as tamoxifen as an adjuvant
treatment in patients.
We thank Ms C. Victor-Smith for her help in this publication.
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